

# Xu Steven Xu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/955852/publications.pdf>

Version: 2024-02-01

22  
papers

332  
citations

840776

11  
h-index

839539

18  
g-index

22  
all docs

22  
docs citations

22  
times ranked

533  
citing authors

#	ARTICLE	IF	CITATIONS
1	A retrospective analysis using deep-learning models for prediction of survival outcome and benefit of adjuvant chemotherapy in stage II/III colorectal cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 1955-1963.	2.5	8
2	Bias correction for multiple covariate analysis using empirical bayesian estimation in mixed-effects models for longitudinal data. <i>Computational Biology and Chemistry</i> , 2022, 99, 107697.	2.3	0
3	SCEBE: an efficient and scalable algorithm for genome-wide association studies on longitudinal outcomes with mixed-effects modeling. <i>Briefings in Bioinformatics</i> , 2021, 22, .	6.5	5
4	A forward selection algorithm to identify mutually exclusive alterations in cancer studies. <i>Journal of Human Genetics</i> , 2021, 66, 509-518.	2.3	4
5	Adaptive weighted sum tests via LASSO method in multi-locus family-based association analysis. <i>Computational Biology and Chemistry</i> , 2020, 88, 107320.	2.3	3
6	Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses. <i>Advances in Therapy</i> , 2020, 37, 1464-1478.	2.9	8
7	A novel quantification of information for longitudinal data analyzed by mixed-effects modeling. <i>Pharmaceutical Statistics</i> , 2020, 19, 388-398.	1.3	2
8	Full covariate modelling approach in population pharmacokinetics: understanding the underlying hypothesis tests and implications of multiplicity. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 1525-1534.	2.4	17
9	Influence of Disease and Patient Characteristics on Daratumumab Exposure and Clinical Outcomes in Relapsed or Refractory Multiple Myeloma. <i>Clinical Pharmacokinetics</i> , 2018, 57, 529-538.	3.5	24
10	Pharmacokinetics and Exposure-Response Analyses of Daratumumab in Combination Therapy Regimens for Patients with Multiple Myeloma. <i>Advances in Therapy</i> , 2018, 35, 1859-1872.	2.9	23
11	Modeling the Relationship Between Exposure to Abiraterone and Prostate-Specific Antigen Dynamics in Patients with Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Pharmacokinetics</i> , 2017, 56, 55-63.	3.5	16
12	Response to -The Role of FcRn in the Pharmacokinetics of Biologics in Patients with Multiple Myeloma- <i>Clinical Pharmacology and Therapeutics</i> , 2017, 102, 905-905.	4.7	5
13	Further Evaluation of Covariate Analysis using Empirical Bayes Estimates in Population Pharmacokinetics: the Perception of Shrinkage and Likelihood Ratio Test. <i>AAPS Journal</i> , 2017, 19, 264-273.	4.4	11
14	Modeling of Bounded Outcome Scores with Data on the Boundaries: Application to Disability Assessment for Dementia Scores in Alzheimer's Disease. <i>AAPS Journal</i> , 2014, 16, 1271-1281.	4.4	12
15	Mixed-effects beta regression for modeling continuous bounded outcome scores using NONMEM when data are not on the boundaries. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2013, 40, 537-544.	1.8	19
16	Pharmacokinetic and Pharmacodynamic Modeling of Opioid-Induced Gastrointestinal Side Effects in Patients Receiving Tapentadol IR and Oxycodone IR. <i>Pharmaceutical Research</i> , 2012, 29, 2555-2564.	3.5	21
17	Shrinkage in Nonlinear Mixed-Effects Population Models: Quantification, Influencing Factors, and Impact. <i>AAPS Journal</i> , 2012, 14, 927-936.	4.4	34
18	Analysis of dose-response in flexible dose titration clinical studies. <i>Pharmaceutical Statistics</i> , 2012, 11, 280-286.	1.3	13

#	ARTICLE	IF	CITATIONS
19	Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with acute coronary syndromes. <i>British Journal of Clinical Pharmacology</i> , 2012, 74, 86-97.	2.4	47
20	Modeling delayed drug effect using discrete-time nonlinear autoregressive models: a connection with indirect response models. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2011, 38, 353-367.	1.8	5
21	Impact of low percentage of data below the quantification limit on parameter estimates of pharmacokinetic models. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2011, 38, 423-432.	1.8	29
22	Population Pharmacokinetics of Tapentadol Immediate Release (IR) in Healthy Subjects and Patients with Moderate or Severe Pain. <i>Clinical Pharmacokinetics</i> , 2010, 49, 671-682.	3.5	26